(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 November 2013 (21.11.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/171696 A1

(51) International Patent Classification:
G01N 33/50 (2006.01) *G01N 33/68* (2006.01)

(21) International Application Number:
PCT/IB2013/053979

(22) International Filing Date:
15 May 2013 (15.05.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
12168121.7 15 May 2012 (15.05.2012) EP

(72) Inventor; and
(71) Applicant : **SAURAT, Jean, Hilaire** [FR/CH]; 22 rue de l'Athénée, CH-1206 Geneve (CH).

(74) Agents: **BUGNION GENÈVE** et al.; 10, route de Florissant, Case Postale 375, CH-1211 Geneva 12 (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2013/171696 A1

(54) Title: METHOD FOR IDENTIFYING LIGANDS OF THE AHR RECEPTOR HAVING THERAPEUTIC SEBOSUPPRESSIVE ACTIVITY, AND SAID LIGANDS

Fig.2



(57) Abstract: A method for sorting substances for the purpose of determining their capacity for sebosuppressive activity in topical skin treatment, comprising an *in vivo* test, the said *in vivo* test comprising the following steps: -choosing a substance from among the ligands of the AhR receptor; -choosing a mammal expressing the CYP1A1 gene; -treating via topical route part of the skin of the said mammal comprising sebaceous glands, with a composition comprising the said substance, following a dose/ response/response time protocol; -examining by immunohistochemical staining the expression of CYP1A in sebaceous glands of the said part of the skin of the said mammal; -selecting the said substance as a function of the sequence of onset of immunohistochemical staining in several different types of cells of the said sebaceous glands. Pharmaceutical composition for topical use intended to reduce sebogenesis, characterized in that it contains 5,6 benzoflavone as active substance.